Get App

Co-Partners

Associate Partners

you are here: HomeNewsBusiness
Last Updated : May 15, 2019 03:10 PM IST | Source: PTI

Dr Reddy's launches skin treatment drug in US

The company has launched its product, which is generic version of Merck Sharp & Dohme Corp's Cubicin, after obtaining approval from the US Food and Drug Administration (USFDA), the Hyderabad-based firm said in a statement.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Dr Reddy's Laboratories on Wednesday said it has launched Daptomycin for injection, used for treating complicated skin infections, in the US market.

The company has launched its product, which is generic version of Merck Sharp & Dohme Corp's Cubicin, after obtaining approval from the US Food and Drug Administration (USFDA), the Hyderabad-based firm said in a statement.

According to IQVIA Health, the Cubicin for injection (daptomycin for injection) brand and generics had sales of around USD 640.8 million for the most recent 12 months ending in March 2019.

Dr Reddy's shares were trading 0.98 per cent up at Rs 2,833.60 on the BSE.
First Published on May 15, 2019 02:40 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant